Geriatric Mobic Dosing
For older adults (≥65 years), start Mobic (meloxicam) at 7.5 mg once daily, which is the same recommended starting dose as for younger adults.
FDA-Approved Dosing
The FDA label for Mobic does not specify a reduced starting dose for geriatric patients 1. The standard dosing is:
- Starting dose: 7.5 mg once daily for both osteoarthritis and rheumatoid arthritis
- Maximum dose: 15 mg once daily if additional benefit is needed
- Absolute maximum: 15 mg daily regardless of age or formulation
Critical Geriatric Considerations
Elderly patients face substantially higher risks with NSAIDs and require heightened vigilance, even though dose reduction is not mandated 1. The FDA black box warning specifically notes that "elderly patients are at greater risk for serious gastrointestinal events" 1.
Key Risk Factors in Older Adults:
The 2009 JAGS guideline emphasizes that NSAIDs were implicated in 23.5% of adverse drug reaction hospitalizations in older adults 2. Exercise particular caution when patients have:
- Low creatinine clearance (renal impairment)
- History of gastropathy or GI bleeding
- Cardiovascular disease or risk factors
- Congestive heart failure (intravascularly depleted state)
- Concurrent anticoagulation or antiplatelet therapy
Practical Dosing Algorithm:
- Start at 7.5 mg once daily (standard dose) 1
- Use the lowest effective dose for the shortest duration consistent with treatment goals 1
- Consider remaining at 7.5 mg rather than escalating to 15 mg in frail elderly
- Monitor closely for GI symptoms, edema, blood pressure changes, and renal function
- Special population: Hemodialysis patients should not exceed 7.5 mg daily 1
Important Caveats
The pharmacokinetics of meloxicam do not require dose adjustment in the elderly based on age alone 3. However, the increased risk of adverse events—particularly GI bleeding, cardiovascular thrombotic events, and renal toxicity—demands a risk-benefit assessment before initiating therapy 1.
Common pitfall: Assuming all geriatric patients need lower doses. The evidence shows that while elderly patients tolerate standard pharmacokinetics, they experience higher rates of serious complications, making careful patient selection and monitoring more important than automatic dose reduction 2, 3.
Meloxicam's 20-hour half-life allows once-daily dosing, which may improve compliance in older adults 3, but this long half-life also means adverse effects may persist longer if they occur.